XLO

Xilio Therapeutics, Inc.

0.96 USD
-0.05 (-5.14%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Xilio Therapeutics, Inc. stock is up 0.85% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 July’s closed higher than June.

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate.